Recent studies also showed that LBDs, particularly Parkinson's disease, often initiate in the gut and that, in some cases, ...

A fungus that has killed millions of bats across North America has arrived in Arizona, state wildlife officials announced on ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The threat of grapevine pests and diseases is a constant battle, but research driven by the Pierce’s Disease and Glassy-Winged ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

a potentially disease-modifying therapy for Parkinson’s disease (PD) in people with or without a GBA1 mutation. In December 2024, we received approval to initiate our Phase 1b clinical trial of ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

The majority of patients with iRBD experience phenoconversion within 10 years of iRBD onset, progressing into α-synucleinopathies like Parkinson disease (PD) and dementia with Lewy bodies (DLB).

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...